Cohen's Point72 purchased over 8 million shares of C4 Therapeutics within weeks of the company announcing phase 1 trial data ...

The iShares Biotechnology ETF (IBB) provides exposure to healthcare innovation with a focus on the biggest firms by market ...

Joseph Terranova, Senior Managing Director, Virtus Investment Partners, said in a recent program on CNBC that he likes the ...

Breakthroughs in RNA editing and radioligand therapies are poised to take biotech into a new era – driving innovation, growth and new investment opportunities Biotechnology is entering a dynamic new ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

The investment seeks daily investment results, before fees and expenses, of 200% of the daily performance of the NYSE Biotechnology Index. The fund, under normal circumstances, invests at least 80% of ...

Biotech stocks rebound after years of weakness as M&A, lower rates and easing policy fears draw investors back to the sector.

The biotech sector has underperformed the market for many years now, but there are reasons to be optimistic. Click here for ...

A fintech firm and two biotechs recently saw some huge insider buying. However, these were not the only insider purchases of ...

As scientific disinformation skyrockets, the Biotechnology Innovation Organization (BIO)—the world’s largest biotech trade ...

The Australian life sciences sector has the right science, capability and capital to succeed – but that has not always been ...

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund launched on ...